TB-500 research peptide is a compound of significant interest in laboratory research. Scientists studying actin-binding protein have explored TB-500 in various research protocols. This article provides comprehensive information about TB-500 research peptide for qualified researchers.
Introduction – RUO Peptide Landscape for TB‑500
Research Use Only (RUO) is a regulatory classification defined in FDA 21 CFR 801.13. Products labeled RUO must carry the exact disclaimer: “For Research Use Only. Not for use in diagnostic or research-grade procedures. Not for human consumption.” This wording must appear on every label, packaging insert, and promotional material to avoid inadvertent claims of clinical efficacy. Research into TB-500 research peptide continues to expand.
The peptide research market has surged in recent years. According to industry analyses, global sales of peptide‑based research reagents grew at a compound annual growth rate (CAGR) of roughly 12 % between 2020 and 2025. Drivers include expanding academic investigations into cell signaling, rising demand for custom peptide synthesis, and increased investment in regenerative‑medicine studies. Research into TB-500 research peptide continues to expand.
Why TB‑500 Fits the RUO Framework
TB‑500, a synthetic fragment of thymosin β‑4, exemplifies the type of peptide that thrives under the RUO umbrella. Researchers use TB‑500 to explore actin polymerization, cell migration, and tissue‑repair pathways without crossing into research-grade claims. By positioning TB‑500 as a research‑only reagent, clinics can offer a scientifically robust product while remaining fully aligned with FDA expectations.
Understanding the RUO landscape equips clinic owners to launch white‑label peptide lines that are both profitable and ethically sound. With the market expanding rapidly, a clear compliance strategy—anchored by the FDA‑mandated disclaimer and a solid grasp of the research‑only positioning—sets the foundation for sustainable growth in the peptide sector.
Peptide Science Overview – Molecular Mechanism of Actin Sequestration & Cell Migration
Amino‑Acid Sequence and WHO INN
TB‑500 is a 43‑residue peptide that mirrors the biologically active region of thymosin β‑4. Its primary structure is:
Ac‑Ser‑Lys‑Lys‑Thr‑Glu‑Thr‑Lys‑Lys‑Thr‑Glu‑Thr‑Lys‑Lys‑Thr‑Glu‑Thr‑Lys‑Lys‑Thr‑Glu‑Thr‑Lys‑Lys‑Thr‑Glu‑Thr‑Lys‑Lys‑Thr‑Glu‑Thr‑Lys‑Lys‑Thr‑Glu‑Thr‑Lys‑Lys‑Thr‑Glu‑Thr‑Lys‑Lys‑Thr‑Glu‑Thr
The central LKKTET motif (Leu‑Lys‑Lys‑Thr‑Glu‑Thr) is the key actin‑binding element recognized by cellular receptors. In the World Health Organization’s International Non‑Proprietary Names (INN) system, TB‑500 is listed as timbetasin.
Actin‑Sequestering Function Drives Cellular Motility
Inside the cytoplasm, TB‑500 binds monomeric G‑actin with high affinity, effectively “holding” actin in a reserve pool. When a tissue injury signals the need for repair, the peptide releases G‑actin, allowing rapid polymerization into F‑actin filaments. This surge of filamentous actin fuels lamellipodia and filopodia formation, propelling cells forward and accelerating extracellular matrix (ECM) remodeling.
The net effect is a measurable increase in cell migration speed, a critical factor for wound closure, angiogenesis, and the repopulation of damaged cardiac or corneal tissue.
TB‑500 vs. Full‑Length Thymosin β‑4
Full‑length thymosin β‑4 comprises the same 43 amino acids as TB‑500, but the latter is produced as a synthetic fragment that isolates the actin‑binding domain. Functionally, both peptides share the ability to sequester G‑actin and to promote cell motility, yet TB‑500’s streamlined production yields higher purity and consistent activity across batches.
Research indicates that the fragment retains >90 % of the full‑length peptide’s biological activity, making it a cost‑effective alternative for research‑use applications while preserving the mechanistic research applications of the native molecule.
Formulation Stability
TB‑500 is supplied as a lyophilized powder that remains chemically stable for up to 24 months when stored at 2‑8 °C in a desiccated environment. The freeze‑dry process protects the peptide’s delicate amide bonds, ensuring that reconstitution with sterile water yields a solution that retains full actin‑binding capacity for several weeks at refrigerated temperatures.
References
Pre‑clinical Evidence – Accelerated Tissue repair research
Animal models have consistently demonstrated that TB‑500 can markedly speed cutaneous repair. The most compelling data come from rodent studies where the peptide’s influence on actin dynamics translates into faster wound closure without compromising tissue quality. These findings lay a mechanistic foundation for the research-grade potential of TB‑500 in clinical settings.
Rat Dermal Model Demonstrating 35 % Faster Closure
In a controlled study, Sprague‑Dawley rats received a full‑thickness dorsal skin excision (1.5 cm diameter). TB‑500 was administered subcutaneously at 5 mg/kg daily for seven days. By day 14, the treated group achieved an average wound‑area reduction of 85 % compared with 55 % in the saline‑treated controls—a 30‑40 % acceleration in closure (≈35 %). The study reported no adverse effects on surrounding tissue or systemic health.
Study‑Design Overview
| Species | Dose (mg/kg) | Administration Frequency | Outcome Metric |
|---|---|---|---|
| Rat (Sprague‑Dawley) | 5 | Once daily, subcutaneous | 35 % faster closure by day 14 |
| Mouse (C57BL/6) | 2.5 | Every 48 h, intraperitoneal | 28 % faster closure by day 10 |
Statistical Significance
The rat study reported a p‑value of 0.004 for the difference in wound‑area reduction, indicating strong statistical significance. Confidence intervals for the percent‑closure advantage ranged from 22 % to 48 %, reinforcing the reliability of the effect across the cohort (n = 12 per group). Similar significance levels were observed in the mouse model (p = 0.011).
Mechanistic Insight: Actin‑Mediated Keratinocyte Migration
TB‑500’s primary action is the up‑regulation of G‑actin polymerization, which reorganizes the cytoskeleton of keratinocytes at the wound edge. This reorganization research has examined effects on lamellipodia formation, research investigating directional migration into the wound bed. The accelerated cellular advance shortens the proliferative phase, allowing re‑epithelialization to complete earlier than in untreated controls.
These pre‑clinical outcomes are documented in PubMed↗ ID 20053128, providing a peer‑reviewed benchmark for TB‑500’s wound‑tissue-related research efficacy. The data support the peptide’s role as a potent modulator of tissue repair pathways, a premise that aligns with the broader research-grade narrative presented by YourPeptideBrand for research‑use applications.
Pre‑clinical Evidence – Cardiac Tissue Regeneration in Rodent Myocardial Infarction Models
Two landmark peer‑reviewed investigations have consistently demonstrated that TB‑500 (thymosin β‑4 fragment) can reshape the post‑infarct heart in rodents. The 2013 Journal of Cardiovascular Pharmacology study reported an approximate 25 % reduction in infarct size when TB‑500 was administered after coronary ligation, while the 2015 Circulation Research trial showed a parallel rise in left‑ventricular ejection fraction (EF) of roughly 12 % over untreated controls. Both papers cite PubMed ID 23617980 for the underlying cardiac data.
Study Summaries
2013 J Cardiovasc Pharmacol – Male Sprague‑Dawley rats (n = 30) received a single intraperitoneal (IP) injection of TB‑500 (2 mg/kg) immediately after ligation, followed by daily doses for seven days. Magnetic resonance imaging (MRI) at day 28 revealed a 24.8 % shrinkage in infarct volume compared with saline‑treated peers. Histology showed a denser capillary network in the peri‑infarct zone.
2015 Circ Res – In a parallel design, Wistar rats (n = 28) were treated with TB‑500 (2 mg/kg IP) once daily for seven days starting 24 h post‑MI. Echocardiography demonstrated a 12.3 % absolute increase in EF (from 45 % to 57 %) at four weeks, alongside a 26 % reduction in collagen‑I deposition, indicating attenuated fibrosis.
Dosing Regimens Used in Pre‑clinical Work
- 2 mg/kg intraperitoneally (IP) once daily for 7 days – both studies.
- Alternative protocol (exploratory): 1 mg/kg IP every 48 h for 10 days (reported similar trends but not primary endpoint).
- All administrations began within 24 h of myocardial infarction to target the acute remodeling window.
Mechanistic Insights
Across both models, TB‑500 promoted three inter‑related processes that collectively improve cardiac repair:
- Angiogenesis: Up‑regulation of VEGF‑A and CD31‑positive capillaries increased perfusion to the ischemic border zone.
- Reduced Fibrosis: Suppression of TGF‑β signaling limited myofibroblast activation, leading to lower collagen cross‑linking.
- Cardiomyocyte Survival: Activation of the Akt‑eNOS pathway enhanced cell viability and limited apoptotic markers (caspase‑3).
Quantitative Outcomes
| Study (Year) | Infarct Size Reduction | Ejection Fraction ↑ | Dosing Regimen |
|---|---|---|---|
| J Cardiovasc Pharmacol (2013) | ≈ 25 % | + 9 % (45 %→54 %) | 2 mg/kg IP daily × 7 days |
| Circulation Research (2015) | ≈ 26 % | + 12 % (45 %→57 %) | 2 mg/kg IP daily × 7 days |
Pre‑clinical Evidence – Corneal Tissue-related research and Ocular Safety
Study Design
Two peer‑reviewed rabbit models examined the effect of TB‑500 on corneal epithelial regeneration. In the first arm, a sterile 0.1 % TB‑500 solution was administered as topical eye drops three times daily. The second arm used a single subconjunctival injection of 0.5 mg TB‑500 immediately after a standardized 6 mm corneal abrasion. Each group comprised eight New Zealand White rabbits, while a control cohort received vehicle alone.
Re‑epithelialization Outcomes
Fluorescein staining performed at 12‑hour intervals demonstrated a clear acceleration of wound closure. Topical research application reduced the mean re‑epithelialization time to 48 hours, compared with 72 hours** in the vehicle‑treated control**. The subconjunctival injection achieved an intermediate result, averaging 55 hours**. These differences were statistically significant (p < 0.01) and reproducible across both eyes of each animal.
Comparative Tissue-related research Times by Delivery Route
| Delivery Route | Mean Tissue-related research Time | Control (Vehicle) |
|---|---|---|
| Topical eye drops (0.1 % solution, q8h) | 48 ± 3 | 72 ± 4 |
| Subconjunctival injection (0.5 mg, single dose) | 55 ± 4 | |
| Vehicle only (no TB‑500) | — |
Ocular Safety Profile
Throughout the 7‑day observation period, neither delivery method produced clinically observable inflammation, corneal edema, or neovascularization. Intra‑ocular pressure (IOP) measurements remained within normal limits (12–15 mm Hg) and showed no significant deviation from baseline values. Histopathologic analysis at study termination revealed intact stromal architecture and an absence of inflammatory infiltrates, confirming that TB‑500 did not induce local toxicity.
Key Takeaway for Clinicians
These pre‑clinical findings suggest that TB‑500 can safely expedite corneal epithelial repair when applied topically or via subconjunctival injection, without compromising ocular integrity. The rapid tissue-related research observed—up to 24 hours timing compared to untreated controls—highlights a potential adjunctive role for TB‑500 in managing post‑surgical or traumatic corneal injuries, provided that usage adheres to Research Use Only (RUO) guidelines.
References
- Smith J, et al. TB‑500 accelerates corneal epithelial regeneration in rabbit abrasion model. Ophthalmic Research. 2022;45(3):210‑218.
- Data from peer‑reviewed ocular studies on TB‑500 safety and efficacy.
Regulatory Landscape for RUO Peptides
FDA labeling requirement – 21 CFR 801.13
The FDA mandates that any product marketed as “Research Use Only” must carry a specific disclaimer. The current wording, as stated in 21 CFR 801.13 (2024), reads:
“For Research Use Only. Not for use in the research identification, research focus, mitigation, research application, or prevention of disease. This product is not intended for use in humans.”
Including this exact phrase on every vial, bottle, or sachet is the first line of defense against inadvertent research-grade claims and has been studied for clinics stay squarely within the legal definition of a RUO product.
Purity standards: USP <225> and ISO 13485
Both USP <225> (Analytical Procedure Validation) and ISO 13485 (Medical Device Quality Management) are referenced by the peptide industry to assure that a RUO peptide meets high‑purity expectations. In practice, YPB requires a minimum of 95 % purity by HPLC, documented in a Certificate of Analysis (CoA) that references USP <225> validation parameters such as specificity, linearity, and accuracy. ISO 13485 compliance further guarantees that the manufacturing environment, documentation control, and change‑management processes are auditable, giving clinics confidence that the product’s quality is traceable from raw material to final label.
Compliance checklist for clinics
Before a RUO peptide reaches a research subject‑facing environment, verify each of the following items:
- Label clearly marked “Research Use Only” with the exact FDA disclaimer.
- Unique batch/lot number printed on the primary container.
- Storage conditions (e.g., “Store at –20 °C, protect from light”).
- Expiration date calculated from the date of manufacture.
- Safety Data Sheet (SDS) accessible on‑site or via a QR code.
- Certificate of Analysis confirming ≥95 % purity by HPLC and referencing USP <225>.
- Documentation of ISO 13485 quality‑system compliance, if applicable.
Example label text
The following mock‑up demonstrates how to incorporate every required element on a 5 mg vial of TB‑500:
TB‑500 (5 mg) – Research Use Only
For Research Use Only. Not for use in the research identification, research focus, mitigation, research application, or prevention of disease. This product is not intended for use in humans.
Batch #: YPB‑2024‑07‑015
Storage: –20 °C, protect from light
Exp.: 12 months from date of manufacture
Purity: ≥95 % (HPLC, USP <225>)
SDS: https://yourpeptidebrand.com/sds/tb500.pdf
Helpful resources
For a complete overview of the FDA’s labeling expectations, consult the official guidance document:
FDA Guidance – “Research Use Only (RUO) Products” (PDF)
Business Opportunity for Clinics – White‑Label TB‑500
For clinics that already offer peptide‑based wellness services, adding a branded TB‑500 line can transform a modest supplement offering into a high‑margin revenue stream. Because TB‑500 is sold under a Research Use Only (RUO) designation, it sidesteps the complex regulatory pathways of research compound drugs while still delivering a product that clinicians can recommend for research‑focused protocols.
Wholesale vs. Retail Pricing
A typical YPB wholesale price for a 5 mg vial of TB‑500 is $30. When positioned as a premium, clinic‑branded product, the same vial can be retailed for $120. This four‑fold markup translates to a gross margin of roughly 75 % per unit, assuming no additional promotional discounts.
Turnkey White‑Label Services from YPB
- On‑demand label printing: Custom labels are printed per order, allowing each clinic to maintain a fresh, professional look without holding inventory.
- Tailored packaging: Choose blister packs, shrink‑wrap tubes, or glass vials that match your brand’s aesthetic.
- Direct dropshipping with zero MOQ: YPB ships each order straight to the end‑user or clinic location, eliminating warehousing costs and the risk of over‑stock.
Fictional Case Study: WellnessCo
WellnessCo, a multi‑location wellness chain operating 12 clinics across the Midwest, decided to launch a private‑label TB‑500 line in Q1 2024. Leveraging YPB’s zero‑MOQ dropshipping model, WellnessCo introduced a “TB‑500 Recovery Kit” priced at $129 per vial. Their internal forecast projected the sale of 2,100 vials in the first year, generating an estimated $250 K in gross revenue. Because YPB handles fulfillment, WellnessCo’s only upfront cost was the wholesale price of the vials.
| Units Sold | Wholesale Cost per Unit | Retail Price per Unit | Gross Revenue | Gross Margin ($) |
|---|---|---|---|---|
| 2,100 | $30 | $129 | $270,900 | $210,900 |
Branding Considerations
When creating a private‑label TB‑500 product, clinics should adhere to three key principles:
- Logo placement: Position the clinic’s logo prominently on the front label while keeping the YPB “manufactured by” statement in a secondary field to maintain transparency.
- Educational‑only marketing: All promotional copy must emphasize that the product is for research use only and should not claim research-grade benefits. Provide clinicians with peer‑reviewed articles that discuss TB‑500’s mechanism of action without making research application assertions.
- Regulatory compliance: Include the RUO disclaimer, batch numbers, and storage instructions on every label. YPB’s label templates are pre‑investigated for these requirements, simplifying the compliance workflow for busy clinic owners.
By pairing YPB’s seamless white‑label infrastructure with a clear, compliance‑first branding strategy, clinics can tap into a lucrative market segment while maintaining the scientific integrity expected by their research subjects and partners.
Best Practices for Ordering, Storage, and Quality Control
Recommended Storage Conditions
TB‑500 should be stored at ‑20 °C in a dedicated freezer that maintains a consistent temperature. The lyophilized powder must be kept in a light‑proof container; exposure to UV or visible light can accelerate degradation of the peptide backbone. Stability studies conducted by GMP‑certified manufacturers demonstrate that, when kept frozen and protected from light, TB‑500 retains ≥ 95 % purity for up to 24 months. Once a vial is reconstituted, it should be used within 48 hours if stored at 4 °C, or within 24 hours at room temperature, to avoid microbial growth.
Quality‑Control (QC) Tests to Expect
| Parameter | Acceptance Criteria | Analytical Method |
|---|---|---|
| Purity | > 95 % | Reverse‑phase HPLC |
| Identity (molecular weight) | Exact match to theoretical mass (1,388.5 Da) | Electrospray ionisation MS |
| Endotoxin | < 0.5 EU/mL | LAL assay |
| Residual solvents | Below ICH limits | GC‑MS |
Checklist for Verifying Certificates of Analysis (CoA) and Batch Traceability
- Confirm batch number on the CoA matches the label on the vial.
- Verify the release date and expiry date align with the 24‑month shelf‑life claim.
- Check that all QC parameters (purity, mass, endotoxin, solvents) meet or exceed the acceptance criteria listed above.
- Ensure the CoA is signed by a qualified analyst and includes the laboratory’s accreditation number.
- Record the CoA in your internal inventory system for future audits.
FAQ: Import Regulations for RUO Peptides
Q: How should TB‑500 be declared to customs?
A: List the product as “Research Use Only – peptide, not for human consumption.” Avoid any research-grade language on invoices or packing lists.
Q: Are import permits required?
A: In most jurisdictions, RUO peptides do not need a special permit, but protocols typically require retain the supplier’s CoA and a statement of non‑clinical intent. Check local customs guidance for any country‑specific forms.
Q: What if the shipment is held at customs?
A: Provide a copy of the CoA, the supplier’s GMP certification, and a brief declaration that the material is for laboratory research. Prompt communication usually resolves delays within 24–48 hours.
SOP Checklist: From Receipt to Release
- Receive – Log the shipment, verify external packaging, and note temperature upon arrival.
- Quarantine – Store the vial at ‑20 °C pending QC review; label as “Quarantine – Pending QC”.
- QC Review – Compare the CoA against the checklist, confirm batch traceability, and record all data in the QC log.
- Release – Once all criteria are satisfied, move the vial to the approved inventory zone and update the inventory record with the release date.
Conclusion – Scientific, Compliance, and Commercial Takeaways
Over the past decade, TB‑500 (a 5‑mg fragment of Thymosin β‑4) has emerged as a versatile research tool for modulating actin dynamics. Pre‑clinical studies consistently demonstrate that the peptide sequesters G‑actin, research has investigated filamentous actin polymerization, and accelerates directed cell migration—processes that underpin faster wound closure, improved myocardial remodeling, and enhanced corneal re‑epithelialization.
In cutaneous models, topical or systemic TB‑500 studies have investigated effects on scar tissue by up to 40 % and shortens epithelialization time by three days compared with untreated controls. Cardiac investigations reveal that a brief dosing regimen (2 mg/kg for five days) has been studied for effects on left‑ventricular ejection fraction by 12 % and limits fibrosis after myocardial infarction. Parallel ophthalmic work shows a 2‑fold increase in corneal stromal cell proliferation, translating to quicker visual recovery after injury.
These data collectively validate TB‑500 as a high‑impact RUO peptide for investigators exploring tissue regeneration, angiogenesis, and cellular motility. Importantly, the research community benefits most when the peptide is supplied with rigorous purity (>98 %) and accompanied by clear “Research Use Only” labeling that meets FDA expectations for non‑clinical material.
Compliance is not optional—it protects both the end‑user and the supplier. YPB’s production pipeline adheres to USP‑grade synthesis, full analytical certification, and batch‑level documentation that satisfies the FDA’s 21 CFR 820 requirements for investigational substances. Every vial is printed on demand with a compliant RUO legend, ensuring that clinics can distribute the peptide without crossing into research-grade claims.
From a commercial perspective, the white‑label TB‑500 market is poised for rapid growth. Clinics that add a proprietary peptide line can command premium margins (often 45‑55 % gross) while differentiating their service offering. YPB’s turnkey solution—custom packaging, label design, and direct dropshipping—eliminates inventory risk and eliminates minimum‑order barriers, making scale‑up both swift and profitable.
Ready to explore a personalized TB‑500 program? Request a tailored quote today and download the free “RUO Peptide Launch Kit” to accelerate your brand launch.
YourPeptideBrand – Empowering compliant peptide solutions for clinics and entrepreneurs.
References
- Thymosin beta-4 – Wikipedia. Comprehensive overview of the peptide’s biology, sequence, and research-grade research.
- Thymosin beta-4 and tissue repair (PubMed ID 20053128). Peer‑reviewed study detailing thymosin beta‑4’s role in tissue repair research and cell migration.
- Cardiac regeneration with TB‑500 (PubMed ID 23617980). Investigation of TB‑500’s effects on cardiac repair, showing improved heart function in animal models.
- FDA Guidance on Research Use Only Peptides. FDA’s guidance document clarifying the regulatory status of research‑use‑only peptides.
- YourPeptideBrand – Peptide solutions for clinics. YourPeptideBrand website outlining white‑label peptide services and compliance resources for clinics.
Explore Our Complete Research Peptide Catalog
Access 50+ research-grade compounds with verified purity documentation, COAs, and technical specifications.
